Meeting
2022 ASCO Annual Meeting
The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma.
Authors
Sara Kuruvilla
London Health Sciences Centre, London, ON, Canada
Sara Kuruvilla , Brandon M. Meyers , Christina Parker , Anthony C. Nichols , Martin Smoragiewicz , Sebastien J. Hotte , Gregory Russell Pond , Alexander V. Louie , Paul Stewart , Morgan Black , Caitlin Carreau , Justin Lee , Nancy Read , Jinka Sathya , Pencilla Lang , Fung Kevin , Varagur Venkatesan , Richard B. Kim , David A. Palma , Eric Winquist
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Clinical Trial Registration Number
NCT03649048
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS12144)
DOI
10.1200/JCO.2022.40.16_suppl.TPS12144
Abstract #
TPS12144
Poster Bd #
385a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN).
First Author: Jochen H. Lorch
Poster
2023 ASCO Annual Meeting
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
First Author: Robert L. Ferris
Poster
2023 ASCO Annual Meeting
Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
First Author: Chunmei Bai
Poster
2022 ASCO Annual Meeting
Six-year follow-up from the weekly-three-weekly study comparing cisplatin once-a-week to once-every-three-weeks as concurrent chemoradiation for locally advanced head and neck squamous cell carcinoma.
First Author: Vanita Noronha